Evaluation of respiratory Failure in Patients with Chronic Obstructive Pulmonary disease
Main Article Content
Abstract
Objectives: - The aim of the present study is to evaluate the clinical profile, investigations, treatment protocol and the response to the therapy in patient of COPD presenting with Respiratory failure.
Materials and Methods: - All those patient with COPD with respiratory failure admitted in IPD in department of Respiratory Medicine R. D. Gardi Medical College Ujjain included in the study. Patients were evaluated by a detailed history, clinical examination, chest radiograph, arterial blood gas analysis and relevant blood investigation and were put on treatment. All the information was written in a proforma and the results were analysed.
Results: - Majority of the patients were males (83.3%) with mean age of 65 years. In our study, the most common risk factor for COPD with respiratory failure was found to be smoking (80%). Nearly 70% cases were having type 2 respiratory failure. The main causes of exacerbations were bronchospasm(88.3%) and secondary infection (68.4%). 65% of the patients were discharged on room air with medical treatment, 23.3% patients were discharge on home oxygen with medical treatment, 3.33% patients discharged on NIV along with medical treatment and 5 patients died during hospitalization.
Conclusion: - It is very important to take holistic approach toward COPD patient with respiratory failure. Early diagnosis, prompt treatment, pulmonary rehabilitation and vaccination are mainstay of management modalities and to prevent further exacerbation in patients.
Article Details
Section
How to Cite
References
2020 Global Initiative for Chronic Obstructive Lung Disease
Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627–43.
Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006; 367: 1216–19.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global burden of disease and risk factors. Washington: The World Bank, 2006.
Stoller JK, Aboussouan LS. α1-antitrypsin defi ciency. Lancet 2005; 365:2225–36
Hogg JC, `limens W. The pathology of chronic obstructive pulmonary disease. Annual review of pathology 2009; 4:435-59.
[42] Bames PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin lmmunol 2016;138(1):16-27.
Bames PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin lmmunol 2016;138(1):16-27
Brochard L, Isabey D, Piquet J, et al. Reversal of acute exacerbations of chronic
obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990;
: 1523–15.
. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P,et al. Global
strategy for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;
:532- 55.
Global Strategy for the Diagnosis, Management and Prevention of COPD2014.
Located at: Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Nava S, Navalesi P, Conti G. Time of non-invasive ventilation. Intensive Care
Med 2006; 32: 361–370
Anthonisen N, Skeans M, Wise R, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–239.
A P.J. Barnes Systemic manifestations and comorbidities of COPD Eur Respir J 2009; 33: 1165–1185 DOI: 10.1183
Kinnunen, T Säynäjäkangas, Olli Tuuponen, T Keistinen, T2003/03/01 143 6 Impact of comorbidities on the duration of COPD patients' hospital episode 97 10.1053/rmed.2003.1438 Respiratory medicine